This study is currently not recruiting participants.

The Timing of the Re-initiation of Therapeutic Anticoagulation/Antiplatelet Therapy following Neurologic Injury or Neurosurgical Intervention

Study on Timing of Resuming Blood Clot Prevention Therapy After Neurosurgery

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

The purpose of this study is to evaluate the timing of restarting therapeutic anticoagulation/antiplatelet therapy following a neurosurgical intervention or neurologic injury in patients admitted to NeuroCritical Care Unit at Methodist Hospital.

Detailed description of study

The purpose of this study is to evaluate the timing of restarting therapeutic anticoagulation/antiplatelet therapy following a neurosurgical intervention or neurologic injury in patients admitted to NeuroCritical Care Unit at Methodist Hospital.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Healthy
  • Age: 100 years or below
  • Gender: All

This study investigates the timing of restarting therapeutic anticoagulation or antiplatelet therapy in patients who have undergone neurosurgical procedures or experienced neurological injuries. These patients are admitted to the NeuroCritical Care Unit at Methodist Hospital. Anticoagulation and antiplatelet therapies are treatments that help prevent blood clots, which can be crucial after certain medical events.

Participants in this study will be monitored to determine the best time to safely restart these therapies after their surgery or injury. This involves careful observation and documentation of patient outcomes to ensure that restarting these therapies does not lead to any adverse effects.

  • Who can participate: The study is open to patients aged 18 and older who have had a neurosurgical intervention or a neurologic injury and are admitted to the NeuroCritical Care Unit at Methodist Hospital.
  • Study details: Participants will be observed to determine the safe timing for restarting anticoagulation or antiplatelet therapy. Their health outcomes will be closely monitored to ensure safety.
Updated on 19 Feb 2024. Study ID: 1603205691

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team